Crizotinib and Surgery for Long-Term Disease Control in Children and Adolescents With ALK-Positive Inflammatory Myofibroblastic Tumors

PURPOSE: Before anaplastic lymphoma kinase (ALK) inhibitors, treatment options for ALK-positive inflammatory myofibroblastic tumors (AP-IMTs) were unsatisfactory. We retrospectively analyzed the outcome of patients with AP-IMT treated with crizotinib to document response, toxicity, survival, and fea...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:JCO Precis Oncol
Glavni autori: Trahair, Toby, Gifford, Andrew J., Fordham, Ashleigh, Mayoh, Chelsea, Fadia, Mitali, Lukeis, Robyn, Wood, Andrew C., Valvi, Santosh, Walker, Roderick D., Blackburn, James, Heyer, Erin E., Mercer, Tim R., Barbaric, Draga, Marshall, Glenn M., MacKenzie, Karen L.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Clinical Oncology 2019
Teme:
Original Report
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7446396/
https://ncbi.nlm.nih.gov/pubmed/32914017
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/PO.18.00297
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items